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Abstract
The University of Vermont College ofMedicine, in collaboration with
the NHLBI, Alpha-1 Foundation, American Thoracic Society, Cystic
Fibrosis Foundation, European Respiratory Society, International
Society for Cellular Therapy, and the Pulmonary Fibrosis Foundation,
convened a workshop, “StemCells andCell Therapies in Lung Biology
and Lung Diseases,” held July 27 to 30, 2015, at the University of
Vermont. The conference objectives were to review the current
understanding of the role of stem and progenitor cells in lung repair
after injury and to review the current status of cell therapy and ex vivo
bioengineering approaches for lung diseases. These are all rapidly
expanding areas of study that both provide further insight into and
challenge traditional views of mechanisms of lung repair after injury
and pathogenesis of several lung diseases. The goals of the conference
were to summarize the current state of the field, discuss and debate
current controversies, and identify future research directions and
opportunities for both basic and translational research in cell-based
therapies for lung diseases. This 10th anniversary conference was a
followup tofive previous biennial conferences held at theUniversity of
Vermont in 2005, 2007, 2009, 2011, and 2013. Each of those
conferences, also sponsored by the National Institutes of Health,
American Thoracic Society, and respiratory disease foundations, has
been important in helping guide research and funding priorities.
Themajor conference recommendations are summarized at the end of
the report and highlight both the significant progress and major
challenges in these rapidly progressing fields.
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Summary
Overview
This was the sixth in a series of biennial
conferences focused on the rapidly
progressing fields of stem cells, cell
therapies, and ex vivo bioengineering in
lung biology and diseases. Since the last
conference there have been a number of
exciting developments that include but are
not limited to: (1) increased understanding
of the identity and functional roles of
endogenous progenitor cells of the lung
epithelium; (2) progress in understanding
the steps necessary to have induced
pluripotent stem cells differentiate into
both airway and alveolar epithelial cells;
(3) increased delineation of the potential
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roles of mesenchymal stromal cells and
endothelial progenitor cells as cell therapy
agents for a widening range of lung
diseases; (4) a steadily increasing number of
clinical trials, particularly of mesenchymal
stromal cells, in a widening range of lung
diseases; (5) identification of additional cell
populations that may have a role in
treatment of lung diseases; (6) progress
and controversy in ex vivo tracheal
bioengineering; and (7) progress in
development of decellularized whole lungs
as scaffolds for ex vivo lung bioengineering
and as research tools. Conversely, there has
been growth in use of unproven cell-based
therapies for lung diseases (i.e., stem cell
medical tourism), an area of increasing
concern.
However, there remain many questions
in each of these areas. Extensive discussion
of each topic area during the conference
resulted in an updated series of
recommendations on nomenclature,
summarized in Table 1, and updated
overall recommendations for how to best
move each area ahead, summarized in
Table 2.
Introduction
This conference was a follow up to five
previous biennial conferences held at the
University of Vermont in 2005, 2007, 2009,
2011, and 2013 (1–6). Since the last
conference in 2013, investigations of
stem cells, cell therapies, and ex vivo
bioengineering in lung biology and diseases
have continued to rapidly progress.
Exciting advances continue in studies of
embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs), with recent
data demonstrating more convincing
evidence of derivation of cells with
phenotypic and in some cases functional
characteristics of both airway and alveolar
epithelial cells. Significant progress also
continues to be made in investigations of
local (endogenous) stem and progenitor
cells resident in adult lungs. Advances in
lineage tracing approaches, novel uses of
lung injury models, development of lung
organoid cultures, and other techniques
continue to provide important insights into
understanding of the identity and lineage
expansion properties of previously
identified putative endogenous stem and
progenitor populations and demonstrate an
increasingly complex network of cellular
repair after injury. However, ongoing
challenges remain with respect to better
defining, accessing, and manipulating the
appropriate niches and to continue to
devise more refined lineage tracing and
other techniques to define, characterize,
and explore potential therapeutic and/or
pathologic properties of endogenous lung
progenitor cells. This includes studies of
lung cancer stem cells, an area of increasing
focus and high interest that remains
incompletely understood. Another
challenge has been that most previous
studies of endogenous progenitor cells
used mouse models, with ongoing
controversy concerning the identity and
characterization of human progenitor
cells. However, increasing data from
several laboratories are better defining the
physiologic and pathophysiologic roles of
upper airway basal epithelial cells in
homeostasis and in development of chronic
obstructive pulmonary disease (COPD),
lung cancers, and other lung diseases.
Previous conferences and other sources
have suggested guidelines for the
nomenclature of stem and progenitor cells
in the lung. However, precise definitions
and characterizations of specific cell
populations, as well as mesenchymal stem
(stromal) cells and endothelial progenitor
cells, remain in evolution. This reflects in
many respects increasing appreciation that
the phenotypic and functional attributes of
cells are context dependent. Cells previously
considered to be differentiated airway or
alveolar epithelial cells can proliferate and
differentiate into other lung epithelial cell
types under varying circumstances, and as
such paradigms of lung cell behavior are in
evolution. Although less so than in previous
years, the terms “stem cell” and “progenitor
cell” are still used with varying degrees of
clarity and precision by different
investigators and in recent publications.
This continues to complicate comparison of
different investigative approaches and fuller
understanding of the role of endogenous
lung progenitor cells both in normal
homeostasis and in response to different
types of lung injuries. A suggested
glossary of relevant working definitions
applicable to lung, originally presented in
the report of the 2007 conference, has
been updated in consultation with
thought leaders in the relevant fields
and is depicted in Table 1. This glossary
does not necessarily reflect an overall
consensus for the definition of each term
and will undergo continuing evolution as
overall understanding of the cell types
and mechanisms involved in lung repair
continue to be elucidated. Nonetheless, it
remains a useful framework for further
discussion and to guide future
experiments.
Continued preclinical studies of
immunomodulation and paracrine effects of
adult mesenchymal stromal (stem) cells
(MSCs) derived from bonemarrow, adipose,
placental, and other tissues continue to
provide evidence of safety and efficacy in
ameliorating injury and inflammation in
animal models of acute lung injury, asthma,
bronchopulmonary dysplasia, COPD,
sepsis, ventilator-induced lung injury, and
other lung diseases. In parallel, a steadily
increasing number of investigations with
other cell populations, including bone
marrow mononuclear cells and amniotic
fluid (AF)-derived cells, demonstrate
efficacy in ameliorating injury in preclinical
models of lung diseases. In parallel, more
sophisticated understanding of the
mechanisms by which each of these different
cells can act has provided growing insight
into their potential applicability for clinical
lung diseases. There are subsequently a
growing number of clinical investigations
either in progress or planned in a range of
pulmonary diseases, including acute
respiratory distress syndrome (ARDS),
sepsis, bronchopulmonary dysplasia
(BPD), and idiopathic pulmonary fibrosis
as well as continuing trials in COPD
listed on ClinicalTrials.gov that are
taking place in the United States, Canada,
Brazil, Europe, and Australasia. Notably,
a phase I multicenter dose-escalation trial
of bone marrow–derived non–HLA-
matched allogeneic MSCs for patients
with severe ARDS demonstrated
safety without evidence of infusional
toxicities. The phase II trial is underway,
and results are anticipated in the spring
of 2016.
Significant advances also continue to be
made in novel areas of investigation,
particularly increasing exploration of three-
dimensional (3D) culture systems and
bioengineering approaches to generate
functional lung tissue ex vivo. In parallel,
ex vivo bioengineered trachea and upper
airways have been used clinically with
varying degrees of success and have
generated significant controversies about
the approaches used. A significant
challenge will be to develop a fuller
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Table 1. Glossary and definition of terminology
Potency: Sum of developmental or differentiation capacity of a single cell in its normal environment in vivo in the embryo or adult tissue.
A change in potency may occur by dedifferentiation or reprogramming, after transplantation to another site or in response to local
inflammation or injury. Demonstrating this change in potency requires lineage tracing the fate of single cells.
Totipotency: The capacity of a single cell to divide and produce all the differentiated cells in an organism, including extraembryonic tissues
and germ cells, and thus to (re)generate an organism. In mammals, with rare exceptions, only the zygote and early cleavage blastomeres
are totipotent.
Pluripotency: The capacity of a single cell to give rise to differentiated cell types within all three embryonic germ layers and thus to form
all lineages of an organism. A classic example is pluripotent embryo-derived stem cells (ESCs). However, some species differences can
occur; for example, mouse ESCs do not give rise to extraembryonic cell types, but human ESCs can give rise to trophoblasts.
Multipotency: Ability of a cell to form multiple cell types of one or more lineages. Example: hematopoietic stem cells in adults and neural
crest cells in developing embryos
Unipotency: Ability of a cell to give rise to cell types within a single lineage. Example: spermatogonial stem cells can only generate sperm or
sperm-precursor intermediate cells.
Lineage: Differentiated cells in a tissue related to each other by descent from a common precursor cell.
Reprogramming: Change in phenotype of a cell so that its differentiation state or potency is altered. At least two kinds of reprogramming
have been described. In one, the term refers to a process that involves an initial process of dedifferentiation to a state with greater
potency, as in the formation of iPSCs from a differentiated cell such as a fibroblast. Alternatively, the concept of “direct reprogramming”
refers to a switch in phenotype from one lineage to another without going through a multipotent or pluripotential intermediate state. This
usually involves genetic manipulation (e.g., fibroblast to neuronal cell or liver cell) by expression of a few transcription factors or may occur
in injury, for example conversion of pancreatic exocrine cells to hepatocytes in copper deficiency. The ability of Scgb1a11 club cells to
give rise to type 2 alveolar epithelial cells after certain kinds of lung injury may be another example of reprogramming in response to injury.
Dedifferentiation: Change in phenotype of a cell so that it expresses fewer differentiation markers and changes in function, such as an
increase in differentiation potential (e.g., reversion of a differentiated secretory cell to a basal stem cell in the tracheal epithelium and
blastema formation during tissue regeneration in amphibians). In most respects, this is synonymous with reprogramming.
Transdifferentiation: The process by which a single differentiated somatic cell acquires the stable phenotype of a differentiated cell of a
different lineage. The classic example is the differentiation of a pigmented epithelial cell of the amphibian iris (neurectoderm) to a lens cell
(ectoderm). May involve transition through a dedifferentiated intermediate, usually but not necessarily with cell proliferation. The
distinction between transdifferentiation and reprogramming may be semantic.
Epithelial–mesenchymal transition: A developmental process in which epithelial cells acquire phenotypic and functional attributes of
mesenchymal-origin cells, usually fibroblastic cells. Whether this process occurs in adult lungs (or other adult tissues) remains
controversial. In cancer biology, epithelial cells can change shape, polarity, and migratory capacity characteristic of other cell phenotypes,
but whether they have undergone a full lineage transition remains unclear.
Plasticity: Ability of a cell to change its phenotype through the process of dedifferentiation, reprogramming, or transdifferentiation. Mature
differentiated cells may be more difficult to dedifferentiate into an iPSC than are immature cells or tissue stem cells. Another use of the
term plasticity is to describe normally adaptive changes in cell phenotype as they adapt to different environmental conditions.
Embryonic stem cells (ESCs): Cell lines developed from the inner cell mass of a blastocyst stage embryo. ESCs have the capacity for self-
renewal and are pluripotent, having the ability to differentiate into cells of all three germ layers and all adult cell types. Mouse (but not
human) ESCs cannot form extraembryonic tissue such as trophectoderm.
Adult stem cell: Cells from adult tissues, such as bone marrow, intestine, nervous tissue, and epidermis, that have the capacity for long-
term self-renewal and differentiation into cell types specific to the tissue in which they reside. These cells can also regenerate the tissue
after transplantation or injury. In general, adult stem cells are multipotent, having the capacity to differentiate into several different mature
cell types of the parent tissue. The differentiation potential of a single adult stem cell may change after transplantation to a new
environment or in response to local injury/inflammation or after culture. For example, MSCs from adipose tissue can give rise to smooth
muscle, cartilage, or bone when cultured under different conditions and/or in response to specific signaling factors. Although easy to track
in in vitro culture systems using isolated cells, demonstrating this change in potential in vivo requires single cell lineage tracing.
Induced pluripotent stem cell (iPSC): Reprogrammed somatic cells that have undergone a resetting of their differentiated epigenetic states
into a state reminiscent of embryonic stem cells after the expression of reprogramming molecules, such as the transcription factors
Oct 3/4, Sox2, c-Myc, and Klf4. iPSCs are similar to ESCs in morphology, proliferation potential, pluripotent differentiation repertoire, and
global transcriptomic/epigenomic profiles. In vivo implantation of iPSCs results in formation of tissues from all three embryonic germ
layers. iPSCs have been generated from both mouse and human cells.
Progenitor cell: A general term traditionally used to describe any relatively immature cell that has the capacity to proliferate, giving rise to
mature postmitotic cells within a given tissue. More recent evidence suggests that differentiated epithelial cells in the lung can act as
progenitors under certain conditions. Unlike stem cells, progenitor cells are generally believed to have limited or no self-renewal capacity
and may undergo senescence after multiple cell doublings. The literature continues to blur distinctions between uses of the terms “stem”
and “progenitor.”
Transit-amplifying cell: The progeny of a tissue stem cell that retains a relatively undifferentiated character, although more differentiated
than the parent stem cell, and demonstrates a finite capacity for proliferation. One recognized function of transit-amplifying cells is the
generation of a sufficient number of specialized progeny for tissue maintenance or repair. There may be other as-yet-unknown functions.
Obligate progenitor cell: A cell that loses its ability to proliferate once it commits to a differentiation pathway. Intestinal transit amplifying
cells are a traditional example. However, it has recently been demonstrated that some intestinal transit amplifying cells can give rise to
Lgr51 intestinal stem cells after ablation of the resident Lgr51 population.
Facultative progenitor cell: A cell that exhibits differentiated features when in the quiescent state yet has the capacity to proliferate for
normal tissue maintenance and in response to injury. Bronchiolar club cells are an example of this cell type. However, it is becoming
apparent that there are likely multiple populations of club cells, not all of which may function in this respect.
Classical stem cell hierarchy: A stem cell hierarchy in which the adult tissue stem cell actively participates in normal tissue maintenance
and gives rise to transit-amplifying progenitor population. Within this type of hierarchy, renewal potential resides in cells at the top of the
hierarchy (i.e., the stem and transit-amplifying cell), and cells at each successive stage of differentiation become less potent.
(Continued)
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understanding of the underlying cell
biology in the tracheal scaffolds and use
these to advance efficacy of clinical
applications.
Each of these areas is reviewed in the
following sections, followed by overall
recommendations for ongoing and future
studies, depicted in Table 2. The overall
consensus of conference participants was
strongly positive and supportive of
continued extensive and intensive
investigations into each of these areas.
Table 1. (Continued )
Nonclassical stem cell hierarchy: A stem cell hierarchy in which the adult tissue stem cell does not typically participate in normal tissue
maintenance but can be activated to participate in repair after progenitor cell depletion. A related concept is that of population asymmetry
or neutral drift, in which there is no dedicated slow-cycling stem cell but rather a pool of equipotent cells that can give rise to clones of
differentiated progeny. This has been shown for intestine, interfollicular epidermis, testis, and human airway basal cells.
Rapidly renewing tissue: Tissue in which homeostasis is dependent on maintenance of an active mitotic compartment. Rapid turnover of
differentiated cell types requires continuous proliferation of stem and/or transit-amplifying cells. A prototypical rapidly renewing tissue is
the intestinal epithelium.
Slowly renewing tissue: Tissues in which the steady state mitotic index is low. Specialized cell types are long lived and some, perhaps
all, of these cells, the facultative progenitor cells, retain the ability to enter the cell cycle in response to injury or changes in the
microenvironment. The relative stability of the differentiated cell pool is paralleled by infrequent proliferation of stem and progenitor cells.
The lung is an example of a slowly renewing tissue.
Hematopoietic stem cell: Cell that has the capacity for self-renewal and whose progeny differentiate into all of the different blood cell
lineages, including mature leukocytes, erythrocytes, and platelets.
Endothelial progenitor cell: This term has been replaced with the following two categories of cells.
Proangiogenic hematopoietic cell: Bone marrow–derived hematopoietic cells that display the ability to functionally augment vascular
repair and regeneration principally via paracrine mechanisms. Most evidence indicates that the recruited proangiogenic hematopoietic
cells circulate to sites of tissue injury and facilitate resident vascular endothelial cell recruitment to form new vessels but lack direct vessel-
forming ability. In general, most prior uses of the term endothelial progenitor cell have now been demonstrated to be more appropriately
described as effects emanating from proangiogenic hematopoietic cells.
Endothelial colony–forming cell: Rare circulating blood cells that display the ability to adhere to tissue culture plastic or matrix proteins
in vitro, display robust clonal proliferative potential, and generation of cells with endothelial lineage gene expression and in vivo blood
vessel forming potential when implanted in a variety of natural or synthetic scaffolds. Endothelial colony–forming cells have also been
termed blood or late outgrowth endothelial cells and, in some cases, have also been referred to as endothelial progenitor cells.
Mesenchymal stromal (stem) cells: Cells of stromal origin that can self-renew and give rise to progeny that have the ability to differentiate
into a variety of cell lineages. Initially described in a population of bone marrow stromal cells, they were first described as fibroblastic
colony-forming units, subsequently as marrow stromal cells, then as mesenchymal stem cells, and most recently as multipotent
mesenchymal stromal cells or MSCs. MSCs have now been isolated from a wide variety of tissues, including umbilical cord blood, Wharton’s
jelly, placenta, adipose tissue, and lung. The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy
has published the minimal criteria for defining (human) MSCs in 2006 (116). However, this definition is being reinvigorated as it has become
clear that the functional attributes of MSCs, (i.e., potency in any given application), in combination with cell surface markers, differentiation
capacity, source, or culture conditions, will provide a more relevant framework for study and potential therapeutic use of MSCs (38).
Fibrocyte: A cell in the subset of circulating leukocytes that produce collagen and home to sites of inflammation. The identity and
phenotypic characterization of circulating fibrocytes is more firmly established than that for EPCs. However, whether fibrocytes originate
from bone marrow lymphoid or myeloid progenitors remains unclear. These cells express the cell surface markers CD34, CD45, CD13,
and MHC II and also express type 1 collagen and fibronectin.
Airway basal stem cells: Cells present within the pseudostratified airway epithelium that are rich in hemidesmosomal connections that
anchor the epithelium to the basement membrane. These cells are characterized by the variable expression of p63 and cytokeratins (K)5
and 14. There are more K5-positive basal cells in the airway than p63-positive cells. Not all K5-positive cells express p63 at steady state.
K14 is expressed in self-renewing basal cells and is only present in rare basal cells at steady state. In the pseudostratified proximal airway
epithelium, basal cells function as stem cells that give rise to ciliated and secretory cells. Recently, cells with some features of basal cells were
described in the distal lung. The extent of the molecular and function similarity of these cells to basal cells of the upper airways is not clear.
Bronchiolar stem cell: A term applied to a population of naphthalene-resistant Scgb1a1lo, Scb3a2hi expressing cells that localize to
neuroepithelial bodies and the bronchoalveolar duct junction of the rodent lung. These cells proliferate infrequently in the steady state but
increase their proliferative rate after depletion of mature club cells by naphthalene. Lineage tracing studies indicate that these cells have
the ability to self-renew and to give rise to Scgb1a1 club cells and ciliated cells after injury. Apart from naphthalene resistance, there is no
evidence that these cells have a higher capacity for functioning as facultative progenitors than Scgb1a11 club cells. Human correlates
have not yet been identified.
Bronchioalveolar stem cell (BASC): A term applied to a rare population of cells (,1 per terminal bronchiole) located at the bronchoalveolar
duct junction in the mouse lung identified in vivo by dual labeling with Scgb1a1 and Sftpc and by resistance to destruction with
naphthalene or bleomycin. In culture, dual-positive cells can be enriched by FACS by selecting for cells that also express Sca1 and CD24.
However, these markers can also be expressed on other cells. The BASCs can self-renew and give rise to progeny that express either
alveolar epithelial lineage markers such as Sftpc, or aquaporin 5, or progeny that express airway epithelial lineage markers such as
Scgb1a1. Currently, it is unknown if BASCs or club cells have any true phenotypic or functional distinction, as there is no evidence that the
dual-positive cells are any more likely than single-positive Scgb1a1 club cell abilities to give rise to type 2 and type 1 cells either in culture
or in vivo after injury. Notably, there are currently no known BASC-specific markers to distinguish them from club cells in vivo. However, in
three-dimensional cocultures, single BASCs are multipotent, with the ability to produce alveolar or airway lineages. Human correlates
have not yet been identified.
Definition of abbreviations: FACS = fluorescence-activated cell sorter; iPSC = induced pluripotent stem cell; MHC=major histocompatibility complex;
MSC=mesenchymal stromal cell.
Modified by permission from Reference 1. The authors gratefully acknowledge input and discussion toward updating of this table from the following
individuals: Christina Barkauskas, Brian Davis, Massimo Dominici, John Engelhardt, Amy Firth, Brigitte Gomperts, Erica Herzog, Carla Kim, Darrell Kotton,
Laertis Ikonomou, Luis Ortiz, Darwin Prockop, Susan Reynolds, Duncan Stewart, Barry Stripp, and Mervin Yoder.
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Table 2. Overall conference summary recommendations and questions for further study
Fundamental/basic
For studies evaluating putative engraftment of any type of cell, including endogenous lung progenitor cells and/or iPSC-derived lung cells,
as either lung epithelial, interstitial, and pulmonary vascular cells, advanced histologic imaging techniques (e.g., confocal microscopy,
deconvolution microscopy, electron microscopy, laser capture dissection, etc.) must be used to avoid being misled by inadequate
photomicroscopy and immunohistochemical approaches. Imaging techniques must be used in combination with appropriate statistical
and other quantitative analyses of functional cell engraftment to allow for an unbiased assessment of engraftment efficiency.
Continue to elucidate mechanisms of potential recruitment, mobilization, and homing of circulating or therapeutically administered cells to
lung epithelial, interstitial, and pulmonary vascular compartments for purposes of either engraftment or of immunomodulation.
Continue to encourage new research to elucidate molecular programs for development of lung cell phenotypes. Incorporate technological
advances including single cell sorting and analyses, CRISPR/Caspase, and advanced microarray approaches.
Continue to refine the nomenclature used in study of endogenous and exogenous lung stem and progenitor cells.
Comparatively identify and study endogenous stem/progenitor cell populations between different lung compartments and between
species.
Identify additional cell surface markers that characterize lung cell populations for use in visualization and sorting techniques.
Increase focus on study of endogenous pulmonary vascular and interstitial progenitor populations.
Continue to develop robust and consistent methodologies for the study of endogenous lung stem and progenitor cell populations. This
includes exploration of different lung injury models that provide individually novel and grouped complementary data.
Develop more sophisticated tools to identify, mimic, and study ex vivo the relevant microenvironments (niches) for study of endogenous
lung progenitor/stem cells.
Continue to develop functional outcome assessments for endogenous progenitor/stem cells.
Elucidate how endogenous lung stem and progenitor cells are regulated in normal development and in diseases.
Identify and characterize putative lung cancer stem cells and regulatory mechanisms guiding their behavior.
Continue to elucidate mechanisms by which embryonic and induced pluripotent stem cells develop into lung cells/tissue.
Comparative assessments of different ESC and iPSC differentiation protocols. Should protocols be standardized?
Devise better definitions of “lung in a dish” studies. Is expression of a few phenotypic genes enough? What functional assays are currently
available and how can these be expanded?
Continue to develop disease-specific populations of ESCs and iPSCs, for example for cystic fibrosis and alpha-1 antitrypsin deficiency,
with the recognition that no strategy has yet been devised to overcome the propensity of ESCs and iPSCs to produce tumors. Expand
use of these cell populations for drug screening and as tools for probing basic disease-specific molecular and cellular pathophysiology.
Continue to develop approaches for ex vivo engineered trachea and large airways for clinical use in both pediatric and adult patients.
Increase focus on producing biologically epithelialized and otherwise functional scaffolds. Increase studies on the underlying biology of
engineered tracheal scaffolds.
Continue to explore lung tissue bioengineering approaches, such as artificial matrices, 3D culture systems, 3D bioprinting, and other novel
approaches, for generating lung ex vivo and in vivo from stem cells, including systems that facilitate vascular development.
Develop standards for potential clinical use of ex vivo engineered trachea and lung.
What is the optimal environment for growing and/or maintaining lungs ex vivo? Develop advanced bioreactor systems for doing this.
Evaluate effect of environmental influences, including oxygen tension, and mechanical forces, including stretch and compression
pressure, on development of lung from stem and progenitor cells.
Incorporate studies of pulmonary nervous and lymphatic structure and function in ex vivo lung bioengineering.
Strong focus must be placed on understanding immunomodulatory and other mechanisms of cell therapy approaches in different specific
preclinical lung disease models.
Improved preclinical models of lung diseases are necessary.
Disseminate information about and encourage use of existing core services, facilities, and web links.
Actively foster interinstitutional, multidisciplinary research collaborations and consortiums as well as clinical/basic partnerships. Include a
program of education on lung diseases and stem cell biology. A partial list includes NHLBI Production Assistance for Cellular Therapies
(PACT), NCRR stem cell facilities, GMP Vector Cores, small animal mechanics, and computed tomography scanner facilities at several
pulmonary centers.
Translational/clinical
Support high-quality translational studies focused on cell-based therapy for human lung diseases. Preclinical models will provide proof of
concept; however, these must be relevant to the corresponding human lung disease. Disease-specific models, including large animal
models where feasible, should be used and/or developed for lung diseases.
Basic/translational/preclinical studies should include rigorous comparisons of different cell preparations with respect to both outcome and
toxicological/safety endpoints. For example, it remains unclear which MSC or EPC preparation (species and tissue source, laboratory
source, processing, route of administration, dosing, vehicle, etc.) is optimal for clinical trials in different lung diseases
Incorporate rigorous techniques to unambiguously identify outcome measures in cell therapy studies. Preclinical models require clinically
relevant functional outcome measures (e.g., pulmonary physiology/mechanics, electrophysiology, and other techniques).
Continue to expand well-designed and appropriately regulated clinical investigations of cell-based therapies for pulmonary diseases and
critical illnesses. This includes full consideration of ethical issues involved, particularly which patients should be initially studied.
Develop uniform criteria for outcome measures and clinical assessments in cell therapy trials and in patients who receive engineered
tracheal implantations or lung implantations when applicable.
Provide increased clinical support for cell therapy trials in lung diseases. This includes infrastructure, use of NIH resources such as the
PACT program, and the NCRR/NIH Center for Preparation and Distribution of Adult Stem Cells (MSCs; http://medicine.tamhsc.edu/irm/
msc-distribution.html), coordination among multiple centers, and registry approaches to coordinate smaller clinical investigations.
Clinical trials must include evaluations of potential mechanisms, and this should include mechanistic studies as well as assessments of
functional and safety outcomes. Trials should include, whenever feasible, collection of biologic materials such as lung tissue,
bronchoalveolar lavage fluid, blood, etc. for investigation of mechanisms as well as for toxicology and other safety endpoints.
Correlations between in vitro potency and in vivo actions of the cells being used should be incorporated whenever possible.
(Continued)
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The growing problem of stem cell
medical tourism in the United States and
globally was also addressed. This is a
significant issue that will require
concerted leadership from a coalition of
respiratory disease societies and patient
advocacy groups to provide appropriate
patient, family, and caregiver information
on the current state of cell-based therapies
for lung diseases. A statement prepared by
the American Thoracic Society (ATS)
Respiratory Cell and Molecular Biology
Assembly Stem Cell Working Group
was included in the conference program
and discussed further at the conference.
An updated version of that statement





lung-diseases.pdf and is included as an online
supplement to the conference report.
Methods
The conference was divided into five
sessions, each featuring a plenary speaker,
research talks presented by leading
international investigators, and a panel-led
debate and discussion. There was a
particular focus on talks featuring up-and-
coming junior investigators. As such, each
session featured two research presentations
given by junior investigators selected by the
conference organizing committee and also
two talks by junior investigators chosen by a
competitive abstract review blinded for both
authors and institutions. An expanded
number of trainee travel awards supporting
both oral and poster presentations by junior
investigators and trainees was provided.
This included a new trainee travel award
specifically targeting women and
underserved minority participants. A
continued feature of the 2015 conference
was a session devoted to career development
led by representatives from the Lung
Division of the NHLBI. This session also
featured a mentoring lunch with junior
investigators and trainees having one-on-
one or small-group time with senior
investigators and a dedicated forum for the
challenges and need for increased women
and diversity in the field. A further continued
successful feature of the conference was the
preconference hands-on training session.
These have all been highly successful
additions to the conference and will continue
to be included in future conferences. The
conference also included an expanded
vibrant poster session. The complete
conference program and list of speakers, oral
presentation abstracts, poster abstracts,
trainee travel award winners, organizing
committee, sponsors, and attendees can be
found in the online supplement.
The conference report is a summation
of the research presentations and
accompanying discussions. Each section was
written by the moderator of that particular
section, with introduction and conclusions
written by the conference co-chairs, Drs.
Wagner and Weiss. Drs. Wagner and Weiss
collated and edited the final sections to
produce the completed draft. The
information in Tables 1 and 2 was based on
comparable tables in previous conference
reports and was updated with contributions
from each author on the basis of
discussions that occurred at the conference.
The conference was accredited and
monitored by the University Of Vermont
Office Of Continuing Medical Education,
which received Accreditation with
Commendation from theAccreditationCouncil
for Continuing Medical Education for their
efforts to provide evidence-based education
that is free from commercial influence.
In keeping with the Accreditation
Council for Continuing Medical Education
Standards of Commercial Support, the
following safeguards were implemented for
this program to ensure an environment free
of commercial bias: Speakers were sent
faculty letters instructing them on the
Standards of Commercial Support, and each
speaker signed a disclosure and attestation
statement identifying possible conflicts of
interest and attesting that they would
provide evidence-based research/education
free of bias. Four faculty members were
identified with conflicts. Two of these
conflicts were resolved. Two were
employees of a commercial interest
speaking on research related to their
companies’ interests; as such, no credit
was awarded for their lectures. Their
information was deemed worthy of
participation in the conference because of
the importance of discovery and
sharing research. However, because their
employment created a conflict that
could not be resolved, credit was
withheld from their lectures.
Participants were notified of the
presence of commercial support, the lack of
credit for the two lectures, and the
disclosures of the faculty by a notice in the
front of the syllabus packet. In addition, a
disclosure slide was shown at the start of
each day. This allowed the audience to be a
critical judge of the information presented
and make their own conclusions about the
data that were shared.
Table 2. (Continued )
Creation of an international registry to encompass clinical and biological outcomes from all cell therapy–based and ex vivo trachea and
lung bioengineering trials.
Partner with existing networks, such as ARDSNet or ACRC, nonprofit respiratory disease foundations, and/or industry as appropriate to
maximize the scientific and clinical aspects of clinical investigations.
Integrate with other ongoing or planned clinical trials in other disciplines in which relevant pulmonary information may be obtained. For
example, inclusion of pulmonary function testing in trials of MSCs in graft vs. host disease will provide novel and invaluable information
about potential MSC effects on development and the clinical course of bronchiolitis obliterans.
Work with industry to have access to information from relevant clinical trials
All relevant investigators should take a strong stand against stem cell medical tourism and be familiar with the resources available to
patients, caregivers, and all involved health care professionals on the websites of respiratory disease and patient advocacy groups as
well those of the leading stem cell societies, the International Society for Cellular Therapy (ISCT), and the International Society for Stem
Cell Research (ISSCR).
Definition of abbreviations: 3D = three-dimensional; ACRC = Asthma Clinical Research Centers; CRISPR = clustered regularly interspaced short
palindromic repeats; EPC = endothelial progenitor cells; ESC = embryonic stem cells; GMP = good manufacturing practice; iPSC = induced pluripotent
stem cell; MSC =mesenchymal stromal cells; NCRR =National Center for Research Resources; NIH = National Institutes of Health.
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Session 1: Advances and
Controversies in
Tracheal Bioengineering
Clinical transplantation of a tissue-
engineered airway almost a decade ago (7)
spurred huge interest and a number of
parallel investigations. Complex airway
replacement cases are infrequent, but
clinically challenging, and often fatal
without innovative solutions. Lessons
learned from early applications, approved
as compassionate use for single patients, are
broadly relevant to respiratory system
regenerative medicine. In the current era,
scientific underpinnings, ethical review, and
clinical results are being rigorously
scrutinized. The first evening of the
Conference examined the field of tracheal
bioengineering and focused on the
limitations of current approaches and the
promise of new strategies.
Professor Martin Birchall, University
College London, provided a review of the
field and traced the history of tracheal
replacement surgery. He highlighted the
importance of historical lessons, such as the
Neville prosthesis (8, 9); discussed recent
approaches, including aortic autografting
(10) and two-stage chimeric allografts (11);
and reviewed his clinical experience,
including several fascinating individual
cases. In general, the initial approach of
reseeding epithelial and mesenchymal cells
into a decellularized trachea and culture in
a bioreactor before implantation have been
replaced, in part due to clinical urgency, by
use of a decellularized scaffold concurrently
seeded with freshly isolated bone marrow
mesenchymal and airway epithelial cells.
Postoperative courses were recounted, and
Professor Birchall then shared lessons
learned during development of RegenVOX,




Assistance Publique Hôpitaux de Paris,
described clinical experience with aortic
homografting for tracheal or bronchial
replacement, while also providing a
complementary view of overall progress.
Aortic homografting stemmed from
decades of work by Dr. Carpentier, a father
of contemporary cardiac surgery. The size,
elasticity, and infection resistance of the
aorta are counterbalanced by its tendency
to collapse, a shortcoming managed with
intraluminal stenting. The clinical surgical
experience was preceded by step-wise rabbit
and sheep studies with autografts and
allografts (12). Further experimental work
documented the superiority of
cryopreserved over decellularized or
glutaraldehyde-fixed grafts (13). Aortic
allografts have promise to allow lung- or
lobe-sparing resections of the major
bronchi as well as tracheal replacement.
The successful use of a cryopreserved
human aortic allograft supported by a
custom-designed silicon/nitinol stent for a
lobe-sparing sleeve lobectomy operation of
a patient with cancer was described.
Multicenter studies of this approach are
underway in the TRACHBRONCHAR
study (ClinicalTrials.gov identifier:
NCT01331863) being conducted by the
French Group for Airway Transplantation.
Dr. Glenn Green, University of
Michigan, a pediatric otolaryngologist,
presented his work on the management of
tracheobronchomalacia. The traditional
approach is tincture of time, minimally
invasive or invasive mechanical ventilation,
tracheostomy, various reconstructive
surgical procedures, and internal stenting.
Dr. Green detailed the confluence of
advances in complementary fields
supporting development of a stabilizing,
bioresorbable exoskeleton for abnormally
collapsible airways. The process was first
developed in a porcine model (14) and is
based on imaging and 3D reconstruction of
the lesion, followed by virtual design and
3D printing of the external splint and
finally testing of physical properties.
Dr. Green reported on the successful use
of the splinting procedure in three clinical
cases meeting U.S. Food and Drug
Administration (FDA) emergency use
exemption criteria (15). One question that
arose was whether the external stents had
erosion potential similar to early
prostheses, which seemed to be minimal
due to the nature of the stent material.
Future directions include seeking
generalized FDA approval; defining
indications, contraindications, and
complications; outcome after bioresorption;
long-term tissue effects; and endoscopic
approaches.
Based on prior success with vascular
grafts (16), Dr. Laura Niklason, Yale
University, presented current work on
trachea, first outlining criteria for success,
including lateral rigidity, longitudinal
flexibility, easy implantation, avoiding
immunosuppression, development of a
mature respiratory epithelium, and host
integration/vascularization. The innovative
approach first encases nitinol struts in
polyglycolic acid, which are then seeded
with vascular smooth muscle cells and
cultured in a bioreactor. During bioreactor
culture, the polyglycolic acid dissolves and
is eventually replaced with a complex
vascular smooth muscle cell–derived
matrix. Decellularization creates the final
product in which physical and biochemical
properties were characterized. When
implanted orthotopically in rats and vervet
monkeys, ingrowth of respiratory
epithelium and vascularization was
observed, although not uniformly, pointing
to areas for further development.
It is broadly appreciated that successful
airway grafts will require an epithelial lining
to prevent secretion retention, granulation
tissue formation, and restenosis. Professor
Samuel Janes, University College London,
presented the work of his group toward
expanding epithelial cell populations from
small initial biopsies and highlighted the
need for high seeding densities in either
synthetic or native tissue constructs.
Conventional culture methods appear
insufficient for the task, but culture with
irradiated feeder cells in the presence of a
rho kinase inhibitor, as previously reported
(17), enabled dramatic expansion of cells
that remained diploid and competent for
mucociliary differentiation in an orthotopic
tracheal graft model. There was spirited
discussion about identification of somatic
airway epithelial stem cells and the need for
accurate models of progenitor–progeny
relationships.
Session 2: Endogenous Lung
Progenitor Cells
A breadth of respiratory epithelial
progenitor cell types were discussed in this
session, including submucosal cells, basal
cells, neuroendocrine cells, and nasal basal
cells. Comparisons were made between the
stem cell properties of progenitors during
pulmonary homeostasis and disease and the
initiation of cancer. A universal theme of the
presentations was the need for developing
methods to evaluate and understand the
signaling events that maintain progenitors
in their naive state, including their niches.
The session began with Dr. John
Engelhardt, University of Iowa, providing
an overview of the respiratory tree and
corresponding epithelial progenitor niches,
followed by his work detailing how
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canonical Wnt signaling (herein referred to
as Wnt signaling) within the adult proximal
airway stem cell compartments regulated
progenitor expansion after injury. Two
niches in the proximal airway were
evaluated: the intercartilaginous zones of
surface airway epithelium (SAE) and the
tracheal submucosal gland (SMG) (18, 19).
During development, Wnt signaling
induces Lef-1 and decreases Sox2 to initiate
primordial glandular placode formation,
required for SMG development. Using
Wnt-specific lacZ and green fluorescent
protein (GFP) reporter mice, Wnt-active
SMG cells were confined to specific niches
in the SMG and SAE during homeostasis.
In response to naphthalene injury,
SMG and SAE proliferation increased
significantly; however, SMG was fourfold
greater. Wnt-active SMG cells were also
found to be clustered with label-retaining
cells, whereas label-retaining cells were not
Wnt activated. SMG cells were described as
distinct from a basal cell phenotype, and
grafting of SMG cells demonstrated their
multipotent nature and ability to
differentiate to both surface epithelium as
well as submucosal structures. Taken
together, these data suggest that regulation
of Wnt signaling plays an important role in
glandular stem cell lineage specification and
proliferation. However, the precise
regulation of Wnt signaling in glandular
stem cells by ligand expression or otherwise
is unclear, highlighting the necessity for
studying epithelial interactions with the
mesenchyme and their specific niches.
Dr. Renat Shaykhiev, Weill Cornell
Medical College, focused on basal cells and
how the environment influences global gene
expression signatures and how these
signatures relate to cancer. He first
presented a comparison of global gene
expression patterns from proximal to distal
airway epithelium obtained from healthy
nonsmoking individuals and healthy
smokers to define region-specific
pathogenesis associated with disease.
Smoking is the major risk factor for cancer
and induces epithelial hyperplasia
accompanied by genomic alterations.
Oxidant stress was identified as a regulator
of abnormal specification of distal to
proximal epithelium. Previous genomic
basal cell studies identified genes unique to
airway basal cells and highlighted
similarities between ESC genetic signatures,
lung cancer, and basal cells analyzed from
the lungs of smokers (20, 21). A significant
application of these studies applies the
knowledge gleaned from these genetic
signatures to identify precancerous lesions
as well as personalize treatment for disease.
Concepts and conflict associated with
the theory of cancer stem cells were
presented by Dr. Mark Onaitis, Duke
University, followed by a review of his
recently published work determining the cell
of origin and subtype of K-ras–induced lung
cancer (22, 23). He began by posing the
question “What do we call stem cells in
cancer?” The first hierarchical organization
of cancer and the existence of a stem cell
were proposed in 1997 by Bonnet and Dick,
describing human acute myeloid leukemia
(24). Early studies used markers such as
CD133, aldehyde dehydrogenase (ALDH),
and Hoechst dye efflux (termed side
population or SP) to identify cancer stem
cells (25–27), and more recent studies have
demonstrated the importance of genotype
in cancer stem cell–initiating capacity
(28, 29). This theory is controversial, because
the assays used to evaluate initiating cell
potential typically involve severely
immunocompromised mice, in which many
cells will form tumors (30). K-Ras
activation in club cell secretory protein
(CC10) (Scgb1a1)–expressing epithelium
leads to adenocarcinoma in a subset of type
II alveolar cells (ATIIs) and hyperplasia in
the bronchioalveolar duct region in the
absence of bronchiolar tumors (23). These
studies were designed to assess the
difference between bronchiolar and alveolar
epithelium, specifically with regard to
Notch signaling. Xu and colleagues
performed an elegant study, modulating
Notch or Sox2 along with K-Ras in CC10-
expressing epithelium (28). Inhibition of
Notch signaling strongly abrogated alveolar
K-Ras–induced adenocarcinoma formation,
and activation of Notch in bronchiolar
cells promoted K-Ras–induced tumor
formation. Sox2 expression reduced the
expression of Notch transcripts. These
studies defined novel cell-specific
mechanisms by which Sox2-regulated
Notch signaling regulated tumor initiation
and tumor progression in K-Ras–activated
respiratory epithelial cells.
Trainee travel award winner Dr. Laura
Succony, University College London,
presented her recent studies using lineage
tracing of leucine-rich repeats and
immunoglobulin-like domains (LRIG) in
the lung. LRIG proteins regulate signal
transduction and are highly expressed in
skin and gut epithelial stem cells (31).
LRIG1 is known to be an endogenous
inhibitor of receptor tyrosine kinases,
including epidermal growth factor receptor.
In the lung epithelium, the expression of
LRIG1 is down-regulated by tobacco
smoking and further down-regulated in
lung squamous cell carcinoma (32). Basal
cells are the hypothesized origin of
squamous cell carcinoma; however, it is
unknown whether or not they express
LRIG1. Using lineage reporter mice,
LRIG1-expressing cells were labeled with
GFP and sorted by flow cytometry and
localized with immunofluorescent staining.
LRIG1 expression did not enrich a basal cell
population, and expression was limited to
40% of basal cells. However, the LRIG1-
positive basal cells were enriched for
colony-forming unit potential, and clonal
expansion was observed in a spheroid assay.
LRIG1 therefore labels a proliferative
subpopulation population of basal
progenitor cells in lung, similar to skin and
gut, further demonstrating heterogeneity
within lung epithelial stem cell populations.
Dr. Christina Barkauskas, Duke
University, reviewed her recently published
work (33–35) on the concept of epithelial
mesenchymal crosstalk in lung fibrosis and
alveolar homeostasis. Although the FDA
has recently approved drugs that slow the
progression of pulmonary fibrosis, the
underlying mechanisms of disease remain
unclear. Understanding the mechanisms of
disease will help to design more effective
therapies. Dr. Barkauskas and colleagues
identified that ATIIs were stem cells in the
adult lung. These cells are able to self-renew
and give rise to additional ATII and type I
cells. They were the first to demonstrate
that growth and differentiation of these
cells occurred more readily when cultured
with platelet-derived growth factor
receptor-a lung mesenchymal cells,
characterized as lipofibroblasts (34),
illustrating the importance of mesenchymal
cells in alveolar biology. The ability of type I
alveolar epithelial cells (AECs) to
“dedifferentiate” to an ATII lineage in
response to pneumonectomy and tissue
regrowth was presented and challenges
existing paradigms (35). Last, she presented
data linking telomere dysfunction and
alveolar stem cell senescence (33).
Telomerase mutations have been identified
in patients with heritable pulmonary
fibrosis. Shortened telomeres, due to
deletion of the telomeric repeat binding
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factor 2 (Trf2) in AECs, resulted in
decreased colony-forming ability in vitro,
and ATIIs underwent senescence and
acquired a proinflammatory phenotype
in vivo. In response to bleomycin challenge,
deletion of Trf2 in AEC resulted in 100%
mortality. Taken together, these studies
illustrate the importance of maintenance of
ATII stem cell function in lung repair and
regeneration.
Dr. Mitsuru Morimoto, Riken Center
Japan, presented his studies dissecting the
role of Notch signaling in the three-
dimensional structure formation of the
neuroepithelial body (NEB) (36). NEBs are
clusters of neuroendocrine (NE) cells,
which are frequently observed at the
bifurcation points of branching
bronchioles. These NEBs have been
characterized as a progenitor niche for
multiple cell types (37). Stepwise deletion of
Notch receptors from the developing lung
epithelium, combined with Sonic
hedgehog–Cre used to lineage label NE
cells, revealed that three Notch receptors
coordinately regulated the abundance of
NE cells and the size of the neuroendocrine
body (NEB) via interactions between the
NE and Stage-specific embryonic
antigen-11, peri-pNEB, intracellular
domain of NOTCH1, CC10 cells, cells
adjacent to the NE in the NEB. Two-
photon microscopy tracked labeled NE cells
in E13.5 explanted lung organ cultures as
they migrated to the bifurcations. The
conclusion from these studies was that
Notch signaling regulates a stepwise
developmental process in the formation of
the NEB and NE cells localized at
bifurcation points. Future studies will be
necessary to dissect the molecular
mechanisms underlying NEB size
regulation by Notch signaling.
Trainee travel award winner Dr. Dawn
Bravo, Stanford University, translated what
has been discovered with regard to lung
basal epithelial progenitors to the murine
and human nasal epithelium. The human
nasal epithelium harbors an accessible
source of progenitors with potential for cell
therapy, the nasal epithelial basal cell
(NEBC) (38). NEBC progenitors were
found to express both p63 and Keratin5
and localized to the nasal floor crypt. The
isolated p63 NEBCs were found to be
highly proliferative. However, the number
of these cells decreased with age and
mitotic index. After sulfur dioxide or
trichloroacetic acid injury, lineage-tracing
analyses demonstrated that the NEBC
completely regenerated the upper airway
epithelium. Both human and murine
NEBCs also formed nasospheres at a clonal
level. This exciting work indicates the
potential redundancy in airway stem cell
niches, which is an important concept for
tissue regeneration and repair.
Drs. Brigitte Gomperts, Mattell
Children’s Hospital UCLA, Susan
Reynolds, Nationwide Children’s Hospital,
and Barry Stripp, Cedars Sinai, led the
panel discussion and summary. They raised
important questions, including: How do
different injury models and aging impact
the different stem cell populations? Can
and should we use endogenous progenitor
cells before we know everything about
them? Although it may seem
counterintuitive to study a small population
of progenitors as a major contributor to
disease pathologies and repair, the innate
characteristics that define them as a
progenitor cell highlight them as ideal
candidates. These characteristics include
the ability to self-renew or divide
asymmetrically and give rise to a clonal
stem cell offspring as well as a second
daughter that can amplify itself
exponentially (39). Last, the multipotent
differentiation capacity of epithelial
progenitors highlights them as an ideal
candidate to potentially influence abnormal
remodeling and subsequent function, either
through influencing surrounding
mesenchymal and vascular cells or their
direct involvement in the remodeling
process. As an undifferentiated cell
population, reactivation of developmental
programs may be relevant to the activation
of adult stem cells during disease. A
comparison of homeostatic function versus
repair or disease phenotypes, as well as
epithelial–mesenchymal cell interactions,
will be paramount to the development of
therapeutics to treat disease, promote tissue
regeneration, and develop functional graft
systems.
Session 3: ESCs, iPSCs, and
Lung Regeneration
Recent progress and increasing
sophistication in the methodologies to
generate and characterize lung progenitor
cells from ESCs and iPSCs have opened new
perspectives to study lung development and
regeneration. This session was moderated by
Dr. Wellington Cardoso, Columbia
University, and the lectures encompassed
diverse topics ranging from technical
challenges in genome editing and in
obtaining mature cellular phenotypes to
novel applications of reprogramming to
overcome aging of endogenous progenitors,
among others. The major recurring themes
from this session were (1) the development
of the next generation of tools for
researchers in determining factors necessary
for directed differentiation of iPSCs (e.g.,
screening platforms, lung lineage reporters,
etc.); and (2) the new opportunities afforded
by genome editing technologies (clustered
regularly interspaced short palindromic
repeats-caspase [CRISPR-Cas] and
transcription activator-like effector nucleases
[TALEN]) for disease modeling, drug
development, and potential cell-based
therapies in the future.
Dr. Paul Gadue, University of
Pennsylvania, presented an overview of the
field of human pluripotent stem cell
differentiation into lung lineage cells,
highlighting the advancements, pitfalls, and
challenges the field faces. He commented on
the potential therapeutic perspectives
opened by the feasibility of using CRISPR-
Cas gene editing–based approaches.
However, difficulties remain in the
management of this technology, given the
long time and labor-intensive requirements
and the challenge of generating fully
differentiated lung-specific cell subtypes.
Although studies from several groups have
demonstrated the feasibility of generating
NK2 homeobox 1 (NKX2.1)1 lung
precursors (40–42), establishing robust
protocols to generate mature end-stage cells
has proven more challenging. To help
overcome this problem, he described a
novel robotic screening platform, developed
in collaboration with Dr. Jan Jensen
(Cleveland Clinic) to better define in a step-
wise manner the inductive signals that drive
lung development from human pluripotent
stem cells. As proof of principle, he
presented evidence that this platform could
define signaling pathways that regulate
patterning of early endoderm from human
ESCs. These results, derived completely
from a software algorithm to optimize for
the induction of anterior (SOX21) or
posterior (CDX21) cell fates, agreed well
with our knowledge of signaling in
endoderm patterning from various model
organisms. He proposes that these
screening platforms can help identify
programs that generate specific lung
cellular phenotypes.
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Dr. Gadue also discussed the difficulties
arising from species-specific differences in
programming and highlighted the
importance of using the human pluripotent
cell system when mouse models do not
replicate the human biology and disease. He
illustrated some fundamental differences
between human and mouse developmental
programs. He showed that although in mice
the transcription factor GATA6 is dispensable
for gut tube formation, it is crucial for
induction of definitive endoderm in human
pluripotent cells (Paul Gadue, unpublished).
He emphasized the importance of better
understanding the differences in the various
model systems available.
Dr. Chad Cowan, Harvard University,
presented a comprehensive review of
genome-editing technologies (TALEN,
CRISPR/Cas9) and cell-based approaches
for disease modeling in ESCs and iPSCs
(43). His laboratory is using these
technologies to advance our knowledge on
disease mechanisms and therapeutic
targeting of metabolic conditions such as
type 2 diabetes mellitus and coronary artery
disease. He stressed the potential of using
these approaches to gain novel insights into
the mechanisms and management of
pulmonary diseases. He described the
overall strategy, emphasizing the
importance of linking human genotypes to
phenotypes. Key steps included performing
human genome editing (CRISPR, TALEN)
to introduce disease-associated gene
mutations and DNA variants into human
iPSCs, followed by using established
protocols for induction of differentiation of
the engineered human iPSCs into relevant
cell types for studies. With the development
of these iPSC-based models, functional
assays can be performed to gain insights
into pathogenic mechanisms relevant to
disease. The identification of disease-
relevant phenotypes in these human cell–
based models ultimately provides the
opportunity to perform genetic and drug
screens to develop novel therapies. When
combined with resources such as genome-
wide association studies and the
identification of novel DNA variants by
exome sequencing, this approach can be
used to interrogate relevant questions, such
as how naturally occurring human genetic
variation influences susceptibility of only
some patients to pulmonary disease.
Dr. Finn Hawkins, Boston University,
presented his work on the use of TALENs to
generate reporters for the study of specific
lung cell lineages derived from human iPSC-
derived lung progenitors. Dr. Hawkins
provided an overview of the recent progress
in deriving putative lung epithelium from
iPSCs (40–42) and the advantages of using
iPSCs to study early aspects of human
development, previously inaccessible to
researchers. iPSC-based platforms can
provide insights into the transcriptional
and epigenetic programs that control
human lung specification and subsequent
patterning into the full repertoire of the
cells that constitute the postnatal lung
epithelium.
Dr. Hawkins also highlighted the
current hurdles in dissecting the genetic
program of lung development and using this
knowledge to generate clinically relevant,
functional lung epithelium from iPSCs.
Major issues he presented were the
heterogeneity of the cells derived from
current directed differentiation protocols,
the paucity of lung-specific markers, and the
lack of robust functional assays to test
efficiency of these protocols.
Dr. Hawkins then presented new
unpublished work in which he generated
and characterized a TALEN-targeted
reporter NKX2.1-GFP iPSC line. He showed
that the TALEN-targeted NKX2.1-GFP line
allowed identification and purification of
lung progenitor cells generated through a
directed differentiation protocol.
Importantly, global transcriptional profiling
of these cells at key stages of the directed
differentiation program defined the kinetics
of gene expression that leads to lung lineage
specification in this iPSC model. The work
was developed in collaboration with Drs.
Darrell Kotton (Boston University) and
Brian Davis (University of Texas, Houston).
Dr. Amy Firth, Salk Institute, described
her efforts to develop a robust and
reproducible in vitro model of lung
epithelial cell differentiation and how this
model can be used to recapitulate human
lung disease in a dish. She discussed the
step-wise iPSC differentiation protocol
passing through SOX171 and FOXA21
definitive endoderm, SOX21 and FOXA21
anterior foregut endoderm, with NKx2.11
emerging as an early marker of
commitment to a lung progenitor (44). She
used an air–liquid interface to mature these
cells to a pseudostratified polarized layer of
endodermal-derived epithelial cells. This
polarized layer included club cells with
CC101 vesicles, Mucin 5AC1 goblet cells,
and tumor protein 631 basal epithelial cells.
The robust multiciliogenesis observed
occurred only when Notch signaling was
inhibited and was identified by (1) the
assembly of multiple pericentrin-stained
centrioles at the apical surface, (2) the
expression of transcription factor FOXJ1,
and (3) the presence of multiple acetylated
tubulin labeled cilia projections in
individual cells (44).
Dr. Firth also presented some of her
most recent data showing a footprint-free
approach to gene correction of cystic fibrosis
transmembrane conductance factor (CFTR)
DF508 mutant iPSCs using state-of-the-art
CRISPR gene editing technology (45). She
was able to show apical cell surface CFTR
localization and demonstrate functional
correction by recording cyclic adenosine
monophosphate–activated and CFTRinh-
172–sensitive CFTR currents in isolated
epithelial cells from both wild-type and the
CRISPR gene–corrected CFTR mutant, not
seen in the uncorrected mutant iPSC-
derived cells. The CRISPR donor vector was
designed to be seamlessly excised using
piggyBac transposase. This allowed for
increased efficiency of correction without
leaving a genomic footprint from the donor
vector other than the desired correction of
the target DF508 mutation. Her results
open new perspectives for the use of this
approach in cell-based therapy for patients
with lung disease. Dr. Firth is now moving
forward using iPSC and refining her
differentiation model system to identify
novel therapeutic targets for lung diseases,
such as primary ciliary dyskinesia, which has
been difficult to study in a human model
from a developmental perspective (46).
Dr. Lily Guo, trainee travel award
recipient from Toronto General Hospital,
presented on “rejuvenation” of aging
endogenous progenitors by
reprogramming. Aging is known to be
accompanied by a marked decline of stem
and progenitor cell function. In the lung,
aging has been associated with telomerase
dysfunction and reduction of the
proliferative and clonogenic capacities of
these cells, ultimately leading to impaired
tissue maintenance and repair. She
described an optimized protocol in which
transient doxycycline-mediated induction
of iPS reprogramming factors turns aging
ATIIs into young ATII-like cells, turning
off inductive factors before the pluripotent
state. This “interrupted reprogramming”
approach enables expansion of a selected
mature cell type and preserves the
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differentiation potential of the parental
population to generate functional progeny.
She proposes that this novel approach can
potentially address the fundamental issue of
how to overcome the aging of available
cellular resources and enhance regeneration.
Dr. Mirabelle Ho, trainee travel award
recipient from Ottawa Hospital Research
Institute, discussed her research findings on
the cooperative interaction between iPSC-
derived vascular smooth muscle cells
(SMCs) and endothelial cells (ECs) in
vascular network formation. The work was
motivated by the need for better
understanding conditions that improve
vascular development in vitro and
endothelialization of lung scaffolds. Dr. Ho
presented evidence that the integrity of
vascular networks formed in Matrigel
through a combination of ECs and SMCs
persisted for at least 72 hours, compared
with 24 hours when ECs alone were plated.
She showed that this holds true for human
umbilical vein endothelial cells used in
studies to support iPSC-derived SMCs, and
for iPSC-ECs. She found that a 3:1 ratio of
ECs to SMCs was critical for optimal
network formation and stability. Network
persistence may also be attributed to
increases in expression of genes regulating
endothelial function, such as TIE2, CD34,
and Kruppel-like factor 2 in ECs and
angiogenic genes such as vascular
endothelial growth factor. In her discussion,
she stressed that vessel stability can often be
a function of the ratio between angiogenic
angiopoietin Angpt1 and its antagonist
Angpt2. The former affords a stabilizing
effect, whereas the latter reduces stability.
An increase in Angpt1:Angpt2 ratio,
observed on coculture of iPSC-SMCs with
ECs, favored network stability. She
proposes that approaches to revascularize
decellularized lungs/organ scaffolds will
benefit from the combined delivery of both
SMCs and ECs to allow more stable vessels.
The session ended with a lively panel
discussionmoderated by Dr. Darrell Kotton,
Boston University, and Dr. Peter Lelkes,
Temple University. A number of the issues
and questions described above were addressed
in more detail, and directions for focused
future studies are summarized in Table 2.
Session 4: Bioengineering
Approaches to Lung Regeneration:
Julia M. Polak Memorial Session
The fourth session on bioengineering
approaches has been named the
Julia M. Polak Memorial Session in honor
of the many contributions Dame Julia
brought to the field. Moderated this year by
Dr. Harald Ott (Massachusetts General
Hospital, Harvard Medical School), the
session addressed several key questions related
to the bioengineering of lung tissue for the
treatment of end-stage lung disease. In the
featured presentation, Dr. Gordana Vunjak-
Novakovic, Columbia University,
introduced several key concepts of lung
engineering based on decellularized
scaffolds. She showed the design and
construction of a moderate-throughput
bioreactor system enabling culture of
multiple organ scaffolds under controlled
biomimetic conditions. As a group, they
have generated substantial, but sometimes
anecdotal, data on decellularization and
recellularization. Such an approach as what
Dr. Vunjak-Novakovic presented would
enable direct comparison of different culture
protocols and conditions and might enable
us to build on each other’s data. In the
second part of her presentation, Dr.
Vunjak-Novakovic shared her recently
published experimental results on site-
specific seeding of microvolumes into
rodent lung scaffolds via control of droplet
size (47). Site-specific delivery of cells,
growth factors, and small molecules is
highly relevant to our community, because
it may enable the control of site-specific
tissue formation and maturation on the
acellular lung scaffold. To date, the
generation of respiratory epithelium in
appropriate proximo-distal distribution has
proven to be challenging. In the third part
of her presentation Dr. Vunjak-Novakovic
discussed a novel approach to selective
in vivo decellularization in large animals. In
this approach, the contralateral lung and/or
extracorporeal membrane oxygenation can
be used to support the animal while the
right upper lobe is selectively intubated and
decellularized via perfusion through the
selected pulmonary artery.
In the second feature presentation,
Dr. Bryan Brown, University of Pittsburgh,
shared his work on extracellular matrix
(ECM) scaffolds as an inductive template for
in vivo tissue engineering. They have
examined the immune response to
implantable ECM scaffolds with a special
focus on the macrophage polarity and role
in tissue remodeling (48, 49). Dr. Brown
highlighted the fact that mononuclear cells
are the hallmark of early ECM remodeling
and that the macrophage phenotype is a
predictor of histomorphologic outcome of
matrix implants. Dr. Brown went on to
explore the role of ECM age and ECM
degradation products in the programming
of macrophages between M1 and M2
phenotypes (50). Dr. Brown closed his talk
suggesting that the sourcing of tissues for
decellularization, and control of host
response in any particular graft, will be key
to achieving constructive graft remodeling
and tissue homeostasis postimplantation.
Dr. Jenna Balestrini, Yale University,
from Dr. Laura Niklason’s group, presented
data on the comparative biology of
decellularized lung matrix. Several
publications have provided some degree of
compositional analysis of decellularized
lung matrix (51–56). Unfortunately, direct
comparative data between protocols are
somewhat limited, and findings and
conclusions are not always consistent
between different research groups. In her
presentation, Dr. Balestrini discussed a
modified perfusion decellularization
regimen currently applied by Dr. Niklason’s
group, which provides optimized matrix
preservation. This protocol is based on
sodium deoxycholate and Triton X
perfusion via the lung’s vasculature.
Dr. Balestrini also explored two topics
relevant to clinical translation. She showed
species-specific differences in decellularization
and their influence on recellularization
with species-matched and unmatched
endothelial cells. With the understanding
that the ECM serves as a reservoir for
growth factors potentially relevant to cell
differentiation and tissue maturation, and
knowing that some of these signals will be
species specific, they will have to put more
weight on gaining a deeper understanding
of species-specific cell fate on ECM
scaffolds.
Dr. Charlie Xi Ren, Massachusetts
General Hospital, Harvard Medical School,
from Dr. Harald Ott’s group, presented his
work in bioengineering a functional
pulmonary vascular bed using human
iPSC-derived cells (57). Dr. Ren discussed
characteristics of the vascular bed of
acellular lungs and their implications on
seeding techniques. Decellularization leads
to loss of barrier function and hydrostatic
perfusion pressure across the capillary bed
(58). In line with these findings, Dr. Ren
showed that bidirectional seeding from the
artery and vein is necessary to reach the
entire vascular bed. In translating his
findings from a primary cell approach to
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iPSC-derived cells, Dr. Ren showed that
two distinct types of vascular cells,
CD140b-expressing pericytes and CD31-
expressing endothelial cells, could be
derived from undifferentiated iPSCs using a
single protocol of directed differentiation.
He also described a novel organ culture
protocol that directed the resulting
recellularized constructs from an
angiogenic phase to a stabilization phase
and thereby enabled functional maturation.
These lungs showed high levels of
endothelial coverage, decreased
thrombogenicity, partial reconstitution of
barrier function, and perfusability ex vivo
and in vivo. Last, Dr. Ren showed how this
technology was successfully applied to
human-scale lungs, highlighting the
translational importance of his results for
the field of lung bioengineering.
Collin Stabler, Temple University, from
Dr. Peter Lelkes’ group, shared data on
anatomical and integrin-specific
reendothelialization of acellular rodent
lungs. They have focused on physical
methods to optimize cell delivery, including
an integrin-based approach to improve
endothelial cell adhesion and maturation.
In rat lungs, endothelial delivery was
superior when acellular lungs were kept in
the supine position compared with lungs
hanging vertically. In the second part of his
presentation, he examined the integrin-
specific binding of rat microvascular
endothelial cells to ECM proteins, lung
matrix slices, and acellular whole lungs and
concluded that a5b1, a2b1, and a1b1
integrins mediate endothelial cell adhesion
on acellular ECM. These results
complement earlier findings of Dr. Lelkes’
group highlighting the importance of
understanding both the integrin receptor of
seeded phenotypes and the cell-binding
motifs of acellular lung matrix (59).
Travel award recipient Dr. Andrew Le,
Yale University, from Dr. Laura Niklason’s
group, shared advanced methods for
endothelial and epithelial cell seeding and
culture for whole-lung tissue. In his
experiments, Dr. Le examined the
phenotypical fate of primary endothelial
cells, and confirmed the stability of their
phenotype, including important functional
features such as expression of endothelial
nitric oxide synthetase and prostaglandin I2
synthase after seeding onto acellular lung
matrices. These findings resulted in
sustained perfusability after orthotopic
implantation in rats.
Dr. Thomas Petersen, United
Therapeutics Regenerative Medicine, shared
recent advances in moving lung tissue
engineering closer toward its clinical
application from an industry perspective.
Dr. Petersen shared results of successful
implementation of fully automated
perfusion decellularization, showing how
this platform could move toward a future
device production phase. He went on to
discuss issues related to scalable cell
expansion, cell seeding of porcine scaffolds,
and a novel systematic tissue analysis
technique that enables quantitative analysis
of human-scale tissue.
Dr. Franziska Uhl, University of
Vermont, from Dr. Daniel Weiss’ group,
shared her results on how stiffness and
stretch influence cell fate during lung
culture and might translate to biomimetic
culture conditions. In the first part of
her presentation, she shared data on
Wnt/b-catenin–mediated lung repair in a
slice model of intermediate-term ex vivo
lung culture and the difficulty in keeping
healthy, native lung slices along for long
time points (60). She shared unpublished
results on the influence of two-dimensional
and 3D stretch on gene expression profiles
of bronchoalveolar stem cell, type 2 alveolar
epithelial cell, epithelial cell adhesion
molecule1 epithelial progenitor cells, and
mesenchymal stem cells. She also showed
that cyclical stretch in a high-throughput
3D model of human lung matrix culture
promoted high levels of surfactant
protein-C expression in primary epithelial
cells, highlighting the importance of
physiologic biomechanical signals in
maintaining mature cellular phenotypes,
and potentially developing advanced tissue
function (61).
In the final talk of the bioengineering
session, travel award recipient Qi (Eric) Tan,
Mayo Clinic, shared interesting data on
developing a self‐assembling vascularized
airway organoid as a step toward lung
regeneration. Dr. Tan showed self-assembly
and organization of constructs derived
from primary mesenchymal, epithelial, and
endothelial cells. The resulting constructs
matured over several days in culture and
showed organization similar to what has
been shown in liver constructs. He went on
to explore the role of Notch signaling on
epithelial phenotype and examined the
mechanical properties of the resulting
constructs. In a final transplant experiment,
Dr. Tan showed feasibility of implantation
and engraftment of the self-assembled
constructs under the kidney capsule in rats.
The session concluded with a panel
discussion on current progress and future
directions led by Drs. Christine Finck
(Connecticut Children’s Medical Center),
Peter Lelkes, (Temple University), Laura
Niklason (Yale University School of
Medicine), and Angela Panoskaltsis‐
Mortari (University of Minnesota). As a
group, we identified the need for a
concerted regulatory strategy to enable the
development of translational strategies for
iPSC-derived constructs, with special
considerations on autologous versus
allogeneic (banked, matched) cell sourcing.
We discussed the need for preclinical
models enabling maturation and testing of
necessary higher-level function of
regenerated constructs. From a
developmental perspective, epithelial
maturation and site-specific tissue
formation will be key areas of research in
the coming years. From the very engaging
comments from the audience and the
panelists, it became clear that the jury is
certainly still out on which cell type and
scaffold will ultimately enable first-in-man
implants. In summary, the session showed
the substantial progress the lung-
regeneration community has made over the
past years. The acellular lung matrix has
become an important platform for many
disciplines interested in repair and
regeneration, and there is continued
support to further pursue this approach.
As part of this session, talks were also
presented by Drs. John West, University of
California–San Diego, and Graham Parker,
Wayne State. Dr. West, a pioneer in lung
physiology and comparative lung
physiology, gave a fascinating presentation
on the evolution and function of avian
lungs. Potential applications to ex vivo lung
engineering were discussed. Dr. Parker,
editor of Stem Cells and Development, gave
an educational presentation on the good,
bad, and ugly in publishing stem and
progenitor cell studies.
Session 5: Careers in Stem Cells, Cell
Therapies, and Lung Bioengineering
After the successful introduction of this
session in the 2013 conference, this year’s
conference hosted two speakers from the
National Institutes of Health to provide an
update on academic careers in the field,
with a special focus on fostering early
career development.
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The presentations given by Dr.
Timothy Moore, Chief of the Lung Biology
and Diseases Branch at the National
Institutes of Health (NIH)/NHLBI and Dr.
Ghenima Dirami, Scientific Review Officer,
Lung Injury Repair and Remodeling Study
Section, Center for Scientific Review, NIH,
were structured around the different grants
and training opportunities offered by the
NHLBI. Dr. Dirami first gave an overview of
the NIH’s mission as a funding body and
how to navigate the grant process.
Importantly, she explained the general
structure of the NIH and outlined the
different institutions and centers within
the NIH and their corresponding
applications—including the Small Business
Innovation Research and Small Business
Technology Transfer awards. She then
provided an excellent step-by-step guide to
submitting a grant and how to select the
appropriate study section, which she
identified as a key step in a successful grant
process. She explained the general structure
of the peer-review process, including the
different divisions and integrated review
groups, and provided important insight
into study sections and the official review
criteria used to score applications. The NIH
Reporter system was also highlighted as a
tool for young investigators to access
abstracts from previous successful grant
applicants and to gain insight into the types
of grants that have been previously funded
by the different study sections. An overview
of the resubmission policy and process after
unsuccessful submissions was also
provided. Finally, a general overview of the
mechanisms and opportunities available for
new and early-stage investigators was
discussed. This included the various career-
development awards and fellowships
available at the NIH, and the NIH Early
Career Reviewer Program, which aims to
train and educate early scientists to become
critical and well-trained reviewers.
Dr. Moore’s presentation provided
more detail on the training mechanisms
available at the NIH for those pursuing
academic careers in lung stem cells, cell
therapies, and bioengineering. In addition
to its mission to advance scientific
knowledge and human health, a key
mission of the NIH is to promote the
development of the next generation of
researchers and physician-scientists. He
gave a historical overview of the T32
training grants in lung biology, including a
breakdown of the number of predoctoral
and postdoctoral students who have been
or are currently been trained using this
mechanism. In addition, he provided
statistics on the high success rates of T32
trainees who transition to an F32 or a
K award. This aspect was discussed in more
detail in the discussion session. The average
number of years that postdoctoral students
are training has increased dramatically over
the past decade, but the NIH has not
adjusted the number of years at which a
trainee can be on a T32/F32 fellowship
(total of 3 yr) or the number of years that a
trainee can be a postdoctoral fellow before
applying for a K award (4 yr). This
highlights a significant training gap in the
NIH’s program, where there are few
mechanisms to sustain the training period
of young scientists, outside of applying for
extremely limited and competitive private
foundation grants. Although the NIH is
aware of this gap, there are currently no
upcoming changes or programs to address
this gap in training. This is further
complicated by the increasing age of first-
time research grant awardees, which has
increased by about 3 years over the past
decade. Although K awardees have higher
chances of success in receiving their first
research grant, the aforementioned
problems remain a significant hurdle for
the future (62, 63). It was therefore a
recommendation of this session that the
NIH continues to monitor its training
mechanisms and to identify areas where
change could be most effective. Dr. Moore
also discussed the K99/R00 award program
in detail and discussed the special initiatives
for training physician-scientists under this
mechanism. This initiative would provide a
longer period of support during the R00
phase, a stronger enforcement of the
minimum 75% research effort, and
sufficient salary support. He also
highlighted the various potential leverage
points for young investigators, including
alignment with the current consortia and
programs. He concluded his talk by
discussing strategies for writing the training
plan in young investigator grants.
The discussion that followed focused
on the realities of training the next
generation of scientists. Although the NIH
has a set of mechanisms in place, and there is
no doubt that getting on this track of
funding enhances your chance of success,
the landscape is changing. There seem to be
some critical mechanisms missing in terms
of training the next generation of scientists,
including training mechanisms for dual
business-scientist or business-physician-
scientists. There is significant funding
available for Small Business Innovation
Research and Small Business Technology
Transfer grants, yet there are no training
mechanisms available at the NIH for
scientists or physician-scientists to obtain
business or entrepreneurial training in
parallel to their clinical or research
programs. Thus, a second recommendation
coming from this session was that the NIH
should look at initiating new training
programs to fill the current gaps in
knowledge and training timelines for the
next generation of scientists and physician-
scientists.
After the formal presentations and the
poster discussion session, all conference
participants were invited to participate in
the Women’s and Diversity reception. For
the second year, this successful networking
and career session was again led by junior
investigators Drs. Darcy Wagner,
Comprehensive Pneumology, Munich,
Germany and Sarah Gilpin, Harvard
University, who moderated a meaningful
discussion of what diversity means in the
context of research and innovation. This
year’s panel was composed of senior leaders
in the field, who each provided a narrative
of their personal experiences and advice on
navigating academic careers. Unique and
engaging perspectives were provided by
Drs. Susan Reynolds, Gordana Vunjak-
Novakovic, Bernard Thebaud (University of
Ottawa), Angela Panoskaltsis-Mortari, and
Luis Ortiz (University of Pittsburgh). The
lively and informative discussion touched
on many important elements of diversity in
scientific careers.
The recurrent advice to build a
supportive team of mentors was evident
throughout the discussion, as panelists
urged more junior investigators to find
mentors for various aspects of their
professional and personal lives. All of the
senior investigators reiterated that one
mentor is likely not enough to enhance
success and that mentors are not limited to
those at your own institution or even
necessarily in your exact field of research. A
uniqueness of experience was emphasized,
reminding young investigators that success
is defined and can be accomplished in
diverse ways. On the basis of positive
feedback, the organizers are hoping to
expand this session to a full evening
program for the next conference. It is clear
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that there is an ongoing need for a forum to
address questions of mentorship, diversity,
and career development. This important
opportunity for researchers from diverse
backgrounds to interact and develop
supportive relationships will remain a
critical component to future conferences
and will provide an opportunity for young
trainees to ask questions and for senior
investigators to reflect on their mentorship
practices.
Session 6: Endothelial Progenitor
Cells, MSCs, and Cell Therapy
Approaches for Lung Diseases
The main advance since the last edition in
2013 was the initiation/completion of early-
phase clinical trials to test the feasibility and
safety of MSCs in acute inflammatory
diseases. Other highlights included
presentations on the therapeutic potential of
human amnion epithelial cells (hAECs), the
quest for cell-free–based therapies via
microvesicles, superior bioengineering
approaches, and a better understanding of
resident lung MSCs and distal epithelial
progenitor cells in health and disease.
Dr. Duncan Stewart, University of
Ottawa, a pioneer in translating cell therapies
into the clinic for cardiopulmonary diseases,
presented very preliminary data on the use of
MSCs in his most recent Cellular
Immunotherapy for Septic Shock (CISS)
phase I trial. Dr. Stewart introduced the
business concept of “headroom,” which
estimates the potential value of innovative
new therapies on the basis of a patient’s
quality of life improvement. He highlighted
the strong economic rationale for cell
therapy in severe sepsis on the basis of its
large headroom (high mortality/high disease
burden) compared with myocardial
infarction (low mortality/mid-to-high
disease burden).
Dr. Stewart then presented the
scientific rationale for testing MSCs in septic
shock, on the basis of (1) their established
antiinflammatory and immune-modulatory
function (64), (2) a systematic review of all
preclinical MSC studies in sepsis models
(n = 21) demonstrating benefit in
reducing overall mortality (L. McIntyre and
colleagues, unpublished results), and (3) a
systematic review and metaanalysis of more
than 100 patients enrolled in clinical trials
with MSCs for various indications
suggesting safety of MSCs (65).
The current CISS study is a phase I single-
center, open-label safety and dose-escalation
trial of allogeneic bone marrow–derived MSCs
in septic shock in up to nine patients with an
observational arm with no intervention
(n = 18–24). The primary objectives are to
define the safety profile and a tolerable dose
of MSCs. Secondary objectives include the
biological effects of MSCs on serial biomarkers
of inflammation and measures of feasibility
related to trial implementation and
conduct. Recruitment began in May 2015.
At the time of presentation, two patients
had been enrolled in the low-dose group
without adverse events. Patient 1 showed
a dramatic decrease in need for inotropic
support within 8 hours of MSC
administration.
Next, Dr. Euan Wallace, Monash
Institute, Melbourne, presented extensive
preclinical data on hAECs for lung injury (66,
67). hAECS attenuated lung injury and
inflammation in bleomycin-induced fibrosis
in wild-type mice (68, 69). Similar to MSCs,
lung engraftment of human AF stem cells is
extremely low, suggesting an alternate
mechanism of action of these cells (70). In
transgenic mice, Dr. Wallace demonstrated
the crucial interactions of hAECS with
immune modulatory cells. The lack of
efficacy of hAECs to mitigate bleomycin-
induced lung injury in surfactant protein
C–deficient mice—known to have impaired
macrophage function—suggests that hAECs
require normal host macrophage function to
exert their reparative effects (71). Indeed,
hAECs decreased lung macrophage influx,
promoted the M2 healer macrophage
phenotype, and, in vitro, decreased
macrophage migration and increased
macrophage phagocytic activity (72). hAECs
also require regulatory T cells (Tregs) to
exert their beneficial effect. Only the
combined administration of hAECs and
CD451/FoxP31 Tregs or CD451/FoxP32
non-Tregs adoptive transfer into bleomycin-
exposed Rag12/2 mice attenuated lung
fibrosis and polarized macrophages into an
M2 phenotype (73). hAECs also promote
bronchioalveolar stem cell proliferation in a
coculture system (Wallace and colleagues,
unpublished results). Furthermore, hAECS
attenuated pulmonary hypertension and loss
of lung vessel density in a combined
hyperoxia1 LPS neonatal mouse model
of BPD, the chronic lung disease of
prematurity (Zhu and colleagues,
unpublished results). Finally, Dr. Wallace
reported efficient lung injury prevention in
bleomycin-induced fibrosis of conditioned
medium (74) and reduced repair activity of
preterm hAECs compared with term
hAECs. A phase I study of hAECs in
premature infants with established severe
BPD has recently started.
Dr. Fernanda Cruz, Federal University
of Rio de Janeiro, Brazil, provided an
overview of preclinical and clinical activity
on bone marrow–derived mononuclear
cells (BMDMC) for lung repair and
regeneration. Putative advantages of using
this mixture of cells include the low cost,
same-day acquisition of autologous cells
(75), and high lung entrapment of cells
after intravenous infusion (76). First,
Dr. Cruz demonstrated efficacy of BMDMC
in elastase-induced murine emphysema (77)
and possibly the superiority of intratracheal
versus intravenous administration (Cruz,
unpublished). Second, in LPS-induced
ARDS, BMDMC improved survival and
static lung elastance; the number of green
fluorescent protein–positive cells was
higher in the direct lung injury group
(intratracheal LPS) compared with
extrapulmonary (intraperitoneal LPS) (5 vs.
2%) (76). BMDMC obtained from ARDS
mice were equally effective as BMDMC
obtained from control mice (78). Third, in
murine silicosis, BMDMC improved lung
mechanics and histology after intratracheal
instillation of BMDC at 30 days (15 d after
treatment) but not at 60 days. A phase I
trial of endobronchial instillation of
autologous BMDMC in five patients with
silicosis showed feasibility and safety (79).
Plans for a phase II study are underway. In
ovalbumin-induced asthma, BMDMC
decreased eosinophilic inflammation and
airway remodeling (80), independent of the
route of administration (intravenous or
intratracheal) (81).
More recent work attempted to identify
which cell(s) among the mixture of
BMDMC promote(s) the beneficial effects in
experimental asthma. Extensive analysis of
lung inflammation, airway histology,
bronchoalveolar lavage cell count, and
cytokines revealed that the monocyte and
MSC fraction contribute to the beneficial
effects of BMDMC (82). Finally, Dr. Cruz
outlined the design of a phase I/II trial
of intravenous autologous BMDMC in
severe asthma, nonresponsive to steroid,
bronchodilators, and/or anti-IgE.
Dr. Kathleen Liu, University of
California–San Francisco, updated the
audience on her group’s progress in
translating allogeneic human MSC therapy
for ARDS into the clinic. In preclinical
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studies, new mechanisms of action of MSCs
were identified: in mice, human bone
marrow–derived MSCs improved survival
and promoted the resolution of LPS-
induced lung injury in part through the
proresolving lipid mediator Lipoxin A4
(LXA4). In an ex vivo perfused human lung
preparation in which lung injury was
induced by endotoxin or live Escherichia
coli, intratracheal or intravenous delivery of
allogeneic, clinical-grade human MSCs or
MSC-conditioned media attenuated
endothelial and epithelial injury,
accelerated alveolar edema resolution, and
enhanced bacterial killing. These effects
were in part mediated through keratinocyte
growth factor (KGF) (83). The clinical
translation was greatly facilitated by the
access to NIH Production Assistance of
Cellular Therapies (PACT) program
clinical-grade human MSCs. To obtain the
investigational new drug/device, the safety
and efficacy of MSCs were completed in a
large animal model in sheep with severe
lung injury from cottonwood smoke
inhalation and intrapulmonary instillation
of live bacteria (84). Importantly, MSCs lost
their therapeutic efficacy if the washing step
after thawing and before administration
was removed. Dr. Liu then presented the
results of a phase 1 multicenter open-label
dose-escalation trial assessing the feasibility
and safety of human bone marrow–derived
allogeneic MSCs in moderate to severe
ARDS (ClinicalTrials.gov identifier:
NCT01775774) (85). No prespecified
infusion-associated events or treatment-
related adverse events were reported in any
of the nine patients. On the basis of these
results, a phase II trial is currently underway.
Dr. Antoine Monsel, Hôpital Pitié
Salpêtrière, Paris, exploited the paracrine
effect of MSCs through the use of MSC-free
conditioned media (CM) (86). A host of
preclinical studies have demonstrated the
therapeutic benefit of MSC-derived CM in
experimental acute lung injury (87, 88),
BPD (89–95), asthma (96, 97), and COPD
(97). Classic questions remain: best dose,
route and timing of administration, best
manufacturing approach (concentrated
CM, cell starvation, preconditioning), and
entire cocktail administration versus
selected molecules. In this respect, recent
insight into microvesicle biology (98) has
offered interesting alternate approaches for
cell-free therapy, including the use of
exosomes, nanosize (30–120 nm) circular
membrane fragments released from the
endosomal compartment and shed from
the surface membranes, which contain
biologically active growth factors such as
KGF and miRNAs.
Preclinical evidence for the therapeutic
benefit of MSC-derived exosomes in lung
diseases was first demonstrated in hypoxia-
induced pulmonary hypertension in mice
(99). In E. coli endotoxin–induced acute
lung injury in mice, human MSC-derived
microvesicles reduced lung permeability
and inflammation in part through the
expression of KGF mRNA and increased
bacterial clearance and monocyte
phagocytosis (100, 101). In the ex vivo
human lung perfusion model, microvesicles
derived from human MSCs increased
alveolar fluid clearance in a dose-dependent
manner, decreased lung weight gain, and
improved pulmonary vascular resistance.
Thus, microvesicle-based therapies are an
interesting cell-free strategy. Hurdles to be
overcome include the standardization of
the isolation methods, large-scale
manufacturing, and quality monitoring.
Dr. Charles Drinnan, University of
Connecticut Health Center, presented work
on AF stem cells for bioengineering
purposes. AF stem cells, first described in
2007, are multipotent stem cells that can also
differentiate into lung cells (102). A subset
of these cells are MSCs that can undergo
osteo-, adipo-, myo-, neuro-, and
vasculogenesis (103). Dr. Drinnan showed
in a series of in vitro experiments how
various culture conditions such as (1)
culture media (standard AF-MSC medium,
modified small airway growth medium, and
a definitive endoderm1 anterior foregut
epithelium1 lung epithelium cocktail
adapted from various pluripotency
schemes) or (2) culture support (plastic,
matrigel, fibronectin, collagen 1,
decellularized rat lung slurries) modify the
acquisition of lung-specific genes by
AF-MSCs. Decellularized rat lung slurries
seem to be potent in enhancing the
expression of surfactant protein C
and NKX2.1.
Likewise, physical interactions with the
extracellular matrix in controlling stem
cell fate are important (104, 105). In the
lung, physiological stretch promotes
differentiation of alveolar epithelial cells
(106). Using the FlexCell device,
Dr. Drinnan demonstrated how different
stretch regimens combined with the
aforementioned culture conditions affect
the acquisition of distal lung cell markers
by AF-MSCs. Last, Dr. Drinnan showed the
feasibility of seeding undifferentiated
AF-MSC into decellularized lungs and the
acquisition of markers such as TTF-1,
SP-C, neuron-specific class III beta-tubulin,
and paired box gene 8. In summary,
refining various culture conditions may
optimize the lung differentiation potential
of AF-derived MSCs for use in acute and
chronic lung diseases.
Trainee travel award recipient Kathleen
Atkins, Ottawa Hospital Research Institute,
focused on resident lung MSCs in the
developing murine lung (107–109). This is
relevant to BPD, the chronic lung disease of
prematurity characterized by interrupted
alveolar and lung vascular growth (110,
111). Because of the critical window during
which lung injury occurs, BPD may have
long-term respiratory health consequences
reaching into adulthood (112). Exogenous
bone marrow– and cord-derived MSCs
improve lung structure and function in
neonatal rodents exposed to chronic
hyperoxia (113). It remains unclear why
resident lung MSCs do not contribute to
lung repair (83, 114). Using a clinically
relevant model in which neonatal
mice were mechanically ventilated for
8 hours and exposed to 40% hyperoxia
(115), the function of resident lung
Sca11CD312CD452EpCAM2 MSCs was
explored. The chondro- and adipogenic
differential potential were unchanged
between control and lung MSCs from
ventilated mice. Compared with
nonventilated control mice, lung MSCs
isolated from ventilated mice showed
higher levels of insulin growth factor–
binding protein 2, 3, 9, and 10; the
antiangiokines tissue inhibitor of
metalloproteinase, thrombospondin 2,
Serpin E1, and Serpin F1; and the
proinflammatory cytokines Pentraxin-3,
monocyte chemoattractant protein-1, and
stromal cell–derived factor 1. Conditioned
media generated from lung MSCs of
ventilated mice were less efficient in wound
closure in an alveolar epithelial cell scratch
assay compared with nonventilated
controls. Preliminary RNA seq analysis also
suggests differences in the transcriptome of
lung MSCs of ventilated mice. A better
understanding of resident lung MSCs in
lung health and disease may enable the
development of enhanced cell products.
Trainee travel award recipient Dr.
Carole Schmoldt, University of Giessen,
Germany, presented original work on
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lung epithelial progenitor cells (EpiSPC)
for lung regeneration after virus-induced
lung injury (116, 117). On the basis of
previous work by McQualter and colleagues
(118), Dr. Schmoldt isolated two
populations from the distal alveolar
epithelial cell pool from murine lungs:
CD491CD312CD452EpCamhigh
EpiSPCa, and the EpCamlow fraction–
labeled type 2 AECs (AEC II). EpiSPC also
expressed the cell surface markers CD104
and Sca-1 and form organoids in culture
that express proSPC and CC10. A genome
array on EpiSPC and AEC II isolated from
mock-infected mice and mice infected with
the PR8 strain of influenza virus revealed a
clear antiviral response by EpiSPC on the
basis of increased gene expression IFN
signaling, virus resistance, and cytokine
pathways.
Wnt/b‐catenin is important for stem
cell regulation and repair (119). In a series
of in vitro and in vivo experiments in
influenza-infected mouse lung epithelial
cell line 12 cells and AEC II and in EpiSPC
isolated from infected mice, Wnt/b‐
catenin–dependent transcription
impairment seems to serve as an immune
evasion therapy, because the Wnt/b‐catenin
activation led to a decrease in viral
replication, whereas Wnt/b‐catenin
inhibition increased viral replication
(120). Fibroblast growth factor 10 (FGF10)/
fibroblast growth factor receptor 2b
(Fgfr2b), downstream of Wnt/b‐catenin, a
crucial growth factor in lung development
and repair (121), promotes the proliferation
of EpiSPC in vitro. Furthermore, influenza
virus decreased Fgfr2b expression in mouse
lung epithelial cell line 12 cells after ex vivo
infection and EpiSPC Fgfr2b expression
and EpiSPC proliferation after in vivo
infection. Inactivation of FGF10/Fgfr2 after
influenza virus infection in transgenic
Rosa26rtTA/1;tet(O)sFgfr2b/1 mice that
express a dominant‐negative soluble Fgfr2b
lead to decreased EpiSPC proliferation,
increased lung permeability, and decreased
body weight. Thus, Wnt/b‐catenin
signaling is activated in response to
influenza virus infection and enhances
the antiviral response. Wnt/b‐catenin
also participates in lung repair through
activation of FGF10/FGFR2b. Influenza
virus infection impairs Wnt/b‐catenin–
dependent transcription as an immune
evasion mechanism, which likely impacts the
regenerative EpiSPC response.
Session 7: Summation and Directions
The above session was followed by intense
discussions that summarized the evolution
of the field. Unlike in previous years, the
question was not “if” clinical trials should
be initiated, but “when.” To illustrate the
appropriate timing for a phase I trial,
Dr. Donald Fink from the FDA used
Dr. Duncan Stewart’s efforts as a state-of-the-
art example of careful and successful
clinical translation of cell-based therapies
through the provision of a rationale,
reproducible results, a mechanism of action
and preclinical toxicity, and safety data.
Regulatory issues around cell-free products
were also discussed: conditioned media or
exosomes are not considered cell products.
Dr. Fink also emphasized the need for
disease-specific potency assays early on for
quality control and to predict in vivo
efficacy of the cell product. Heated
discussions around stem cell tourism
for lung diseases also took place,
emphasizing the clear need for an
international strategy on how to best
inform patients and family members about
cell-based therapies.
The conference directors, Drs. Weiss
and Wagner, then worked through a
detailed summary of key points of each
session and invited further comment from
the audience. Key points for future
research and funding directions are
summarized in Table 2.
Summary
A continuing accumulation of data in both
animal models and clinical trials suggests
that cell-based therapies and novel
bioengineering approaches may be potential
therapeutic strategies for lung repair and
remodeling after injury. In parallel, further
understanding of the role of endogenous
lung progenitor cells will provide further
insight into mechanisms of lung
development and repair after injury and
may also provide novel therapeutic
strategies. Remarkable progress has been
made in each of these areas since the last
conference 2 years ago. We hope that the
workshop recommendations (Table 2)
will spark new research that will provide
further understanding of mechanisms of
repair of lung injury and further provide a
sound scientific basis for therapeutic use of
stem and cell therapies in lung diseases. n
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AMERICAN THORACIC SOCIETY DOCUMENTS
S276 AnnalsATS Volume 13 Number 8| August 2016
 
safety study of intrabronchial instillation of bone marrow-derived
mononuclear cells in patients with silicosis. BMC Pulm Med 2015;
15:66.
80 Abreu SC, Antunes MA, Maron-Gutierrez T, Cruz FF, Carmo LG,
Ornellas DS, Junior HC, Absaber AM, Parra ER, Capelozzi VL, et al.
Effects of bone marrow-derived mononuclear cells on airway and
lung parenchyma remodeling in a murine model of chronic allergic
inflammation. Respir Physiol Neurobiol 2011;175:153–163.
81 Abreu SC, Antunes MA, Maron-Gutierrez T, Cruz FF, Ornellas DS,
Silva AL, Diaz BL, Ab’Saber AM, Capelozzi VL, Xisto DG, et al. Bone
marrow mononuclear cell therapy in experimental allergic asthma:
intratracheal versus intravenous administration. Respir Physiol
Neurobiol 2013;185:615–624.
82 Cruz FC, Borg ZD, Goodwin M, Coffey AL, Wagner DE, Rocco PR,
Weiss DJ. CD11b+ and Sca-1+ cells exert the main beneficial
effects of systemically administered bone marrow-derived
mononuclear cells in a murine model of mixed Th2/Th17 allergic
airway inflammation. Stem Cells Transl Med 2016;5:488–499.
83 Hennrick KT, Keeton AG, Nanua S, Kijek TG, Goldsmith AM, Sajjan
US, Bentley JK, Lama VN, Moore BB, Schumacher RE, et al. Lung
cells from neonates show a mesenchymal stem cell phenotype. Am
J Respir Crit Care Med 2007;175:1158–1164.
84 Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK,
McAuley DF, McKenna DH, Traber LD, Zhuo H, et al. Human
mesenchymal stem cells reduce the severity of acute lung injury in a
sheep model of bacterial pneumonia. Thorax 2014;69:819–825.
85 Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X,
Cosgrove K, Vojnik R, Calfee CS, Lee JW, et al. Mesenchymal stem
(stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet
Respir Med 2015;3:24–32.
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